National
Romney’s veep options, from bad to worse
Five potential candidates have records hostile to LGBT rights
Amid the media frenzy over who Republican presidential candidate Mitt Romney will select as his running mate, one thing is clear: the leading candidates’ positions on LGBT issues range from bad to downright hostile.
The Washington Blade examined the records of five prospective vice presidential candidates to see where they stand on LGBT issues: former Minnesota Gov. Tim Pawlenty, U.S. Sen. Rob Portman (R-Ohio), U.S. Sen. Marco Rubio (R-Fla.), U.S. Rep. Paul Ryan (R-Wis.) and Louisiana Gov. Bobby Jindal. Each of the potential choices has views on LGBT rights similar to Romney’s, who says he opposes marriage rights for gay couples, but also opposes discrimination — without backing any particular measure to protect LGBT people from discrimination.
One pick that is receiving considerable media attention is Pawlenty, who was a Republican presidential contender early on before he dropped out of the race after his poor showing in the Iowa Ames straw poll. There is media speculation that he tops the list for running mates being vetted by the Romney campaign, although Sunday on CBS’ “Face the Nation” he dismissed the rumors, saying he’s “encouraged people who asked this question in the campaign to look at other prospects.”
Pawlenty took a hardline on marriage over the course of his presidential campaign, signing — albeit belatedly — an anti-gay pledge from the National Organization for Marriage to back a Federal Marriage Amendment, defend the Defense of Marriage Act in court and establish a presidential commission on “religious liberty” to investigate the alleged harassment of opponents of same-sex marriage.
“I don’t think all domestic relationships are the same as traditional marriage,” Pawlenty said on CNN in July. “Marriage between a man and a woman is something that should remain elevated socially, culturally, and practically, legally, morally in our society.”
Another possibility for Romney who is receiving considerable attention is Portman, who’s served for two decades as a public official as a member of Congress, the U.S. Trade Representative and director of the Office of Management & Budget. On Tuesday, Portman appeared to be cozying up to Romney, telling the Washington Reuters Summit the candidate would be “willing to risk being a one-term president in order to make the tough decisions that are going to be required.”
The Ohio senator made headlines when he suggested that he opposes the Employment Non-Discrimination Act, after telling ThinkProgress that he has concerns about litigation that could follow if the legislation were passed.
“What I’m concerned about in Paycheck Fairness and other legislation like that is the fact that it will spawn a lot of litigation the way the legislation is written,” Portman said. “So you don’t want it to be a boon to lawyers, you want it to actually help people. But no one should discriminate.”
Tico Almeida, president of Freedom to Work, said the perception that Portman is opposed to ENDA is inconsistent with what he’s heard based on meetings with the senator’s staff and said Portman — along with “a significant number” of Republican senators — may vote “yes” on the bill.
“Based on Freedom to Work’s conversations with the office of Sen. Portman, we believe he might vote ‘yes’ on ENDA if Sen. Harry Reid brings it to the floor of the Senate for a vote,” Almeida said. “The only way to know for sure is for Reid to fulfill a promise he made three years ago by finally bringing ENDA to the Senate floor.”
Portman’s office didn’t immediately respond to a request to clarify the senator’s position on ENDA. Any such vote in favor of ENDA would represent a change of heart for Portman based on his anti-gay votes while serving as a member of the U.S. House from 1993 to 2005. Portman voted in favor of the Defense of Marriage Act and the Federal Marriage Amendment. In 1999, Portman voted in favor of barring D.C. same-sex couples from adopting children.
Chris Seelbach, a gay Cincinnati City Council member, said he doubts Portman would support LGBT issues if he were elected as vice president based on those votes.
“Based on Sen. Portman’s consistent votes against LGBT families, it seems very clear that he would be no friend to the gay community if elected vice president,” Seelbach said.
Romney is expected to name his running mate prior to the Republican National Convention, which will take place this year during the week of Aug. 27 in Tampa, Fla. Andrea Saul, a Romney campaign spokesperson, declined to comment on any possible selection saying, “We don’t discuss the VP process, sorry.”
The No. 2 person on the Republican presidential ticket could have bearing on how gay Americans who lean conservative may vote in November. Christian Berle, deputy executive director of the Log Cabin Republicans, said the selection will impact whether the organization endorses Romney this fall.
“As Log Cabin Republicans considers many factors in making a potential endorsement, we’ll of course take into account whom will be in such a critical position,” Berle said. “If Gov. Romney and Republicans want to be successful in November, they must improve their position among moderates, women and younger voters with a message entirely focused around jobs and the economy.”
It’s for this reason that Berle praised Ryan, who was among the 159 Republicans who voted for a gay-only version of the Employment Non-Discrimination Act when it came to the House floor in 2007. Ryan later said he took criticism for his vote, but acknowledged he has gay friends, saying, “They didn’t roll out of bed one morning and choose to be gay. That’s who they are.”
Berle said Ryan’s vote for the non-inclusive ENDA in 2007 demonstrates that he recognizes “like all Americans that the workplace needs to be about meritocracy and productivity.”
But besides this vote, Ryan’s record on LGBT issues has hardly been stellar. Ryan voted in the subsequent Congress against hate crimes protection legislation and “Don’t Ask, Don’t Tell” repeal. The lawmaker also expressed opposition to same-sex marriage, saying on NBC’s “Meet the Press” last year, “I support the Wisconsin Amendment to define marriage between a man and a woman.”
Katie Belanger, executive director of Fair Wisconsin, dismissed the notion that a Vice President Ryan would be a champion for LGBT equality upon taking the oath of office.
“Rep. Ryan has maintained a consistently anti-fairness voting record on issues of importance to our community, during the last five congressional sessions, including voting in 2002 against a policy that members of Congress voluntarily adopted to prohibit discrimination based on sexual orientation in their own congressional offices,” she said.
U.S. Sen. Marco Rubio (photo by Gage Skidmore via wikimedia)
Many pundits have speculated that Rubio is on the list of names Romney is considering for his running mate. Romney said earlier this month the senator was being “thoroughly vetted” for a position as No. 2 on his ticket.
New to federal office, Rubio hasn’t been called on to vote on LGBT issues yet, although he’s been closely aligned with the conservative Tea Party movement. Among his “no” votes were against an LGBT-inclusive reauthorization of the Violence Against Women Act.
Rubio has expressed differing views from Romney on the Federal Marriage Amendment, saying “ultimately marriage is regulated by states,” but has expressed opposition to same-sex marriage based on his religious beliefs.
“I believe marriage is a unique and specific institution that is the result of thousands of years of wisdom, which concluded that the ideal — not the only way but certainly the ideal — situation to raise children to become productive and healthy humans is in a home with a father and mother married to each other,” Rubio said.
Nadine Smith, executive director of Equality Florida, said the LGBT community wouldn’t be able to trust Rubio if he were vice president during a Romney administration.
“I don’t think he believes the foolishness he says, he’s pandering as fast as he can, and in that sense, he and Romney are made for each other,” Smith said. “They’re both weather vanes.”
Another potential running mate is Jindal, who was considered a potential candidate for president prior to his widely panned response to President Obama’s State of the Union address in 2009. Last month, Americans for Tax Reform President Grover Norquist praised Jindal in an op-ed for Politico, later reportedly saying “Jindal is a leading option” for vice president.
But Jindal is known for having anti-gay views and maintaining close ties with anti-gay figures. Jindal campaigned for governor on rescinding an order put in place by Democratic Gov. Kathleen Blanco protecting gay state workers from discrimination — a pledge he fulfilled upon taking office.
Once elected, Jindal established a Louisiana Commission on Marriage & Family, appointing to the body anti-gay activists such as the Family Research Council’s Tony Perkins and the Alliance Defense Fund’s Michael Johnson.
SarahJane Brady, managing director of the Forum For Equality Louisiana, said Jindal has “continuously repressed and ignored the needs” of LGBT people in Louisiana.
“Bobby Jindal has proven himself repeatedly to be an enemy of fairness and equality,” Brady said. “Should Gov. Romney choose Bobby Jindal to be his running mate, that would send a message of open hostility to the LGBT community.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Protecting the trans community is not optional for elected allies and candidates
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Child- and pet-proofing your home for the holidays
Long-awaited ‘Pillion’ surpasses the sexy buzz
-
District of Columbia1 day agoReasons to be optimistic about 2026
-
Commentary3 days ago
America is going in the wrong direction for intersex children
-
District of Columbia3 days ago
Rush reopens after renewing suspended liquor license
-
Real Estate4 days ago
Child- and pet-proofing your home for the holidays
